SCHEMBL17215728

SCHEMBL17215728

CCc1ccc(/[C]=N\OCc2ccc(-c3ccccc3)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 2/20 0.42
▸ AGXT P21549 2/20 0.42
▸ NPC1 O15118 3/20 0.40
▸ RAB9A P51151 3/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ GAA P10253 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ NAAA Q02083 4/20 0.38
▸ GSTP1 P09211 1/20 0.37
▸ CYP2A6 P11509 1/20 0.37
▸ CYP1A1 P04798 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP1B1 Q16678 1/20 0.36
▸ FFAR1 O14842 1/20 0.35
▸ S1PR1 P21453 1/20 0.35
▸ TAAR1 Q96RJ0 1/20 0.35
▸ RXRA P19793 1/20 0.35
▸ RXRB P28702 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17215731 1.00 IDO1 (0.42) IDO1AGXTNPC1RAB9ASMN1; SMN2
SCHEMBL17218641 0.92 TP53 (0.47) IDO1NPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL17218644 0.92 TP53 (0.47) IDO1NPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL17217397 0.91 TP53 (0.43) NPC1RAB9ASMN1; SMN2L3MBTL1GAA
SCHEMBL17217395 0.91 TP53 (0.43) NPC1RAB9ASMN1; SMN2L3MBTL1GAA
SCHEMBL17217275 0.89 IDO1 (0.48) IDO1AGXTNPC1RAB9ASMN1; SMN2
SCHEMBL17217277 0.89 IDO1 (0.48) IDO1AGXTNPC1RAB9ASMN1; SMN2
SCHEMBL17216623 0.89 CYP2A6 (0.45) NPC1RAB9ASMN1; SMN2L3MBTL1GAA
SCHEMBL17216620 0.89 CYP2A6 (0.45) NPC1RAB9ASMN1; SMN2L3MBTL1GAA
SCHEMBL17216360 0.89 AGXT (0.45) AGXTTP53NAAAFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2940012-B1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF SUMITOMO CHEMICAL CO (JP) 2019-01-30 — — EP disclosed
US-9560850-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-02-07 — — US disclosed
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-11-26 — — US disclosed
EP-2940012-A1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF Sumitomo Chemical Company Limited (JP) 2015-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF RTN3, CYP51A1, TCOF1 IDO1 2882/4885AGXT 1423/4885NPC1 1841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback